Endothelin antagonistic peptide

Details Endothelin antagonistic peptide Endothelin antagonistic peptide

C - Chemistry, Metallurgy

07

K

C07K 5/04 (2006.01) A61K 38/04 (2006.01) C07D 209/42 (2006.01) C07K 5/083 (2006.01) C07K 5/087 (2006.01) C07K 14/575 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2124989

ABSTRACT OF THE DISCLOSURE A peptide derivative of the formula: Image (I) wherein R2 is a hydrogen atom or a lower alkyl group; R3 is a lower alkyl group which is unsubstituted or substituted with a lower alkylthio group, a lower alkenyl group, a cycloalkyl group or a cycloalkyl lower alkyl group wherein optional one to four hydrogen atoms on the ring may independently be replaced by a lower alkyl group, an aryl group, a heteroaryl group, an aryl lower alkyl group or a heteroaryl lower alkyl group; R4 is a hydrogen atom, a lower alkyl group or an acyl group; X and Y are mutually dependent; when X is a group of the formula R11-O-C(=O) or a group of the formula R12R13N-C(=O), Y is a group of the formula: Image (II) wherein R11 is a lower alkyl group or an aryl group, R12 is a lower alkyl group, a cycloalkyl group, a cycloalkyl lower alkyl group, a 1-adamantyl group, or an aryl group or a heteroaryl group wherein optional one or two hydrogen atoms on the ring may independently be replaced by an optional group selected from the group consisting of a lower alkyl group, a lower alkoxy group, a halogen atom, a trifluoromethyl group, a nitro group, an amino group and a formyl amino group, R13 is a hydrogen atom, a lower alkyl group which is unsubstituted or substituted with a hydroxyl group, a cycloalkyl group or a cycloalkyl lower alkyl group, or R12 and R13 form, together with the adjacent nitrogen atom, a 5- to 9-membered nitrogen-containing saturated heterocyclic ring having 4 to 8 carbon atoms (wherein among methylene groups forming the ring, optional one methylene group may be replaced by a thio group, optional one to four hydrogen atoms on the carbon atoms of the heterocyclic ring may independently be replaced by a lower alkyl group or a hydroxy lower alkyl group, and further two adjacent carbon atoms in the heterocyclic ring may form a benzo-fused ring), R5 is a hydrogen atom, or a lower alkyl group or a lower alkenyl group which may have one to three substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a lower alkylthio group, an aryl group and a heteroaryl group, n is 0 or 1, z is a hydroxymethyl group, a group of the formula CO2R61 (wherein R61 is a hydrogen atom or a lower alkyl group), a group of the formula CONR62R63 (wherein each of R62 and R63 is independently a hydrogen atom, an aryl group, a heteroaryl group, or a lower alkyl group which may have one to three substituents selected from the group consisting of a hydroxyl group, a carboxyl group and a sulfo group), a 1H-tetrazol-5-yl group, a sulfo group or a phosphono group, and when X is a group of the formula: Image (III) Y is a group of the formula: Image (IV) wherein R71 is a hydrogen atom, R72 is a lower alkyl group which is unsubstituted or substituted with a lower alkylthio group, a cycloalkyl group, an aryl group or a heteroaryl group, or R71 and R72 together form an alkylene group having 2 to 5 carbon atoms, m is 0, 1 or 2, Q is a group of the formula COOR8 (wherein R8 is a hydrogen atom or a lower alkyl group), a sulfo group or a 1H-tetrazol-5-yl group, each of R91 and R92 is independently a hydrogen atom, or a lower alkyl group or a lower alkenyl group which may have one to three substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a mercapto group, a lower alkylthio group, a carboxyl group, a carbamoyl group, an amino group, a guanidino group, an aryl group and a heteroaryl group, or R91 and R92 together form an alkylene group having 2 to 4 carbon atoms wherein optional one hydrogen atom in the alkylene group may be replaced by a hydroxyl group, and one sulfur atom may be present, and U and W together form a single bond; or a pharmaceutically acceptable salt thereof.

Affiliated with

Also associated with

Rating

Endothelin antagonistic peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endothelin antagonistic peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin antagonistic peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1457169